RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Tongji Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Tongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06280313, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Clinical or pathological diagnosis of hepatocellular carcinoma (HCC) that is unresectable initially or has recurred after surgery.

    Inclusion criterion 3

  3. Child-Pugh score of 5-7.

    Inclusion criterion 6

  4. Ongoing active infection within 7 days after completion of systemic antibiotic therapy.

    Exclusion criterion 8

  5. Splenomegaly with WBC <2.5 × 10\^9/L and PLT <70 × 10\^9/L, or splenomegaly with WBC <2.0 × 10\^9/L or PLT <50 × 10\^9/L.

    Inclusion criterion 9

    Important organ functions meeting the following criteria: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3*ULN, total bilirubin ≤ 3*ULN; International normalized ratio (INR) ≤ 1.5*ULN; prothrombin time ≤ 1.5*ULN; creatinine ≤ 1.5*ULN.

    Inclusion criterion 10

  6. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), positive syphilis serology, untreated active hepatitis (defined as HBV-DNA ≥ 10\^5 copies/ml; HCV-RNA higher than the lower limit of detection for the assay).

    Exclusion criterion 12

  7. Pregnant or lactating women or females with a positive pregnancy test prior to the first dose who have the potential for pregnancy.

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06280313, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients aged 18 to 75 years (inclusive).
  • No prior systemic antitumor treatment or meeting the criteria for splenectomy during treatment.
  • Clinical or pathological diagnosis of hepatocellular carcinoma (HCC) that is unresectable initially or has recurred after surgery.
  • HBV-DNA less than 1*10\^5 copies/ml and undergoing antiviral therapy.
  • ECOG performance status score of 0-1, without significant organ dysfunction.
  • Child-Pugh score of 5-7.
  • Spleen thickness >4.0 cm.
  • History of esophagogastric varices, red signs, or variceal bleeding with or without splenomegaly.
  • Splenomegaly with WBC <2.5 × 10\^9/L and PLT <70 × 10\^9/L, or splenomegaly with WBC <2.0 × 10\^9/L or PLT <50 × 10\^9/L.
  • Important organ functions meeting the following criteria: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3*ULN, total bilirubin ≤ 3*ULN; International normalized ratio (INR) ≤ 1.5*ULN; prothrombin time ≤ 1.5*ULN; creatinine ≤ 1.5*ULN.
  • Able to undergo local treatments such as transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy (HAIC), selective internal radiation therapy with yttrium-90 (SIRT), stereotactic body radiation therapy (SBRT), and ablation (including radiofrequency ablation (RFA) and microwave ablation (MWA)).
  • Willing to provide informed consent.
  • Expected survival time of more than 3 months.

Exclusion Criteria:

  • History of or concurrent active malignancy (excluding malignancies that have been cured for over 5 years or in situ cancers that can be completely cured with adequate treatment).
  • Presence of central nervous system metastasis or a history of brain metastasis.
  • History of organ transplantation.
  • History of surgery in the head, chest, or abdomen within the past six months.
  • Child-Pugh class C liver function or significant ascites.
  • Marked thrombosis in the portal venous system or extensive cancer thrombus in the main portal vein.
  • Activated partial thromboplastin time (APTT) or prothrombin time (PT) exceeding 1.5 times the upper limit of normal (as per the normal values of the clinical trial research center), or evidence of bleeding tendency or history of bleeding within the two months prior to enrollment, regardless of severity.
  • Ongoing active infection within 7 days after completion of systemic antibiotic therapy.
  • Active coronary artery disease, severe/unstable angina, or newly diagnosed angina or myocardial infarction within the past 12 months before enrollment.
  • Thrombotic or embolic events within the past 12 months, such as cerebrovascular accidents (including transient ischemic attacks), pulmonary embolism, or deep vein thrombosis.
  • New York Heart Association (NYHA) class II or above congestive heart failure.
  • Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), positive syphilis serology, untreated active hepatitis (defined as HBV-DNA ≥ 10\^5 copies/ml; HCV-RNA higher than the lower limit of detection for the assay).
  • Any active, known, or suspected autoimmune disease. Stable subjects not requiring systemic immunosuppressive therapy may be included, such as those with type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, and skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, and alopecia).
  • Interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, and acute pneumonia).
  • Pregnant or lactating women or females with a positive pregnancy test prior to the first dose who have the potential for pregnancy.
  • The investigator deems the subject inappropriate for participation in this clinical study due to any clinical or laboratory abnormalities or compliance issues.
  • Severe psychological or mental abnormalities.
  • Participation in another drug clinical trial within the past 4 weeks.
  • Other reasons that the investigator considers unsuitable for enrollment.

Quoted from ClinicalTrials.gov, NCT06280313, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06280313, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06280313